Pharmafile Logo
Pharmafocus logo
Advanced Search

ViiV

Showing 15 posts of 26 posts found.

landing-hero-images1

ViiV’s HIV drug Rukobia gets EC marketing authorisation

February 9, 2021
Manufacturing and Production HIV, ViiV

The European Commission (EC) has authorised ViiV Healthcare’s Rukobia (fostemsavir) 600mg extended-release tablets for use in combination with other antiretroviral …

News
landing-hero-images1

ViiV gets EU approval for children’s HIV treatment

January 13, 2021
Research and Development EU, HIV, ViiV

ViiV Healthcare, the global specialist HIV company, has received marketing authorisation from the European Commission for Tivicay (dolutegravir) 5mg dispersible …

News
1070297_viiv-healthcare-office-16

ViiV Healthcare announces authorisation of Europe’s first long-acting HIV injection

December 21, 2020
Sales and Marketing GlaxoSmithKline, HIV, ViiV

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline, has announced the authorisation of Europe’s first complete long-acting …

News
1920px-hiv-budding-color

ViiV Healthcare’s two drug HIV therapy beats Gilead’s three drug treatment in Phase 3 trial

July 10, 2019
Research and Development AIDS, Dovato, GSK, Gilead, HIV, ViiV, pharma

Pfizer and GlaxoSmithKline’s HIV company, ViiV Healthcare, has said its two-drug combo Dovato (dolutegravir and lamuvidine) met its primary endpoint …

News

Clinical trial will test long acting HIV injection

May 10, 2019
Medical Communications Art, CAB, HIV, Janssen, RPV, ViiV, injectable

A long-acting, injectable HIV drug combo is to be tested in a clinical trial of 350 volunteers with HIV. The …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

April 12, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, BMS, Eisai, Gilead, MSD, Pfizer, ViiV, indivior

This week was an excellent week for recommendations and approvals after Eisai, MSD, Pfizer, BMS and ViiV scored wins. Meanwhile …

News

Monthly injections offer similar efficacy to daily pills in HIV phase 3 trials

March 8, 2019
Medical Communications ATLAS, GSK, HIV, ViiV, flair, injectable

A long acting, injectable two drug regimen developed by Pfizer and GSK joint venture ViiV Healthcare and J&J subsidiary Jannsen, …

News
janssen_latest_logo_on_sign_closer

Janssen says cabotegravir/rilpivirine combo matches three-drug HIV maintenance therapy

February 24, 2016
Research and Development Janssen, ViiV

Janssen has announced 32-week data from an ongoing phase IIb study of an HIV regimen comprised of its rilpivirine and …

News
viiv_healthcare

ViiV completes BMS HIV pipeline purchase

February 23, 2016
Manufacturing and Production, Medical Communications, Research and Development Bristol-Myers Squibb, GSK, HIV, Pfizer, Shionogi, ViiV

ViiV Healthcare has completed its previously-announced acquisition of Bristol-Myers Squibb’s late-stage HIV R&D assets and its portfolio of preclinical and …

News
landing-hero-images1

ViiV Healthcare to acquire Bristol-Myers Squibb’s HIV pipeline drugs

December 18, 2015
Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, HIV, ViiV, ViiV Healthcare

Specialist HIV company ViiV Healthcare has agreed deals worth up to $1.46 billion to purchase Bristol-Myers Squibb’s late stage HIV …

News
HIV infected cell

ViiV in late-stage HIV trial success

September 23, 2015
Research and Development HIV, Triumeq, ViiV, virology

Switching patients to Triumeq, a once-daily combination treatment for HIV, is as effective as remaining on antiretroviral therapy in certain …

News
otsuka image

Otsuka, ViiV and AstraZeneca named in ABPI code complaints

May 26, 2015
Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, Otsuka, PMCPA, ViiV

A ‘senior male employee’ of Otsuka Pharmaceuticals “potentially brought the industry into disrepute” by plying a female healthcare professional with …

News
GSK image

GSK launches new HIV research centre

May 11, 2015
Research and Development, Sales and Marketing AIDS, GSK, HIV, UNC-Chapel Hill, ViiV, qura

GlaxoSmithKline is boosting its philanthropic efforts in R&D into HIV/AIDS by teaming up with academic researchers to launch a new …

News
ViiV founder Dr Manuel Goncalves

Reputation gains from focussing on the patient

May 11, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, HIV, Manuel Goncalves, Pfizer, ViiV

Since being spun-off from GSK and Pfizer, specialist HIV firm ViiV Healthcare has earned the best corporate reputation amongst patients …

Feature
GSk image

Boardroom shuffles at GSK and Roche

May 8, 2015
Medical Communications, Sales and Marketing GSK, Novartis, Roche, ViiV, changes, leadership

GlaxoSmithKline and Roche have announced the latest changes to its leadership teams as the companies regroup for the year ahead. …

News

Latest content

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024